Leerink Partners Initiates Coverage On Voyager Therapeutics with Outperform Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Voyager Therapeutics with an Outperform rating and set a price target of $15.
October 16, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Voyager Therapeutics with an Outperform rating and a price target of $15, indicating positive expectations for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $15 by Leerink Partners suggests a positive outlook for Voyager Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100